A Multi-Concept Theme for Digital Agencies and Startups
Ministry of Health and Family Welfare has issued a directive to ban the manufacture, sale, and distribution of the fixed dose combination drug Glucosamine sulphate potassium chloride+ Methyl Sulphonyl Methane(MSM) + Sodium Borate+ Copper Sulphate pentahydrate+ Manganese Sulphate + Vitamin D3, Glucosamine Sulphate Sodium Chloride +Manganese +Boron + Zinc + Copper, Glucosamine sulphate + Chondroitin sulphate + Methylsulfonylmethane +Vitamin D3 + Vitamin E + Vitamin C + Selenium +Elemental Zinc +Elemental Manganese + Elemental Chromium + Elemental Copper +Elemental Boron, Glucosamine sulphate + Methyl sufonyl methane + manganese sulphate +Vit E acetate +calcium Carbonate, Glucosamine Sulphate + +Vitamin E acetate + Calcium Pantothenate + Vitamin D3, Glucosamine Sulphate Potassium chloride +Calcium Carbonate from an organic source (oyster shell) eq. to elemental Calcium+ Vitamin D3, Cetyl Myristoleate + Glucosamine Sulphate Potassium chloride + Methyl sulfonyl methane, Glucosamine Sulphate Potassium chloride + Methyl sulfonyl methane +Calcium carbonate +Vitamin E+ Manganese, Glucosamine Sulphate Potassium chloride + Calcium carbonate + Methyl sulfonyl methane +Vit D3, Glucosamine Sulphate Potassium + Methyl sulphate Sodium+ Sulphonyl Methane +Chondroitin Sulphate Sodium+ Calcium Carbonate +Vitamin D3+Sodium Borate+ Cupric Oxide+ Colloidal Silicon Dioxide+ Manganese Chloride, Methocarbamol + Diclofenac Sodium Injection, Paracetamol + Pentazocin, Sucralfate +Domperidone+ Simethicone, Sulfaquinoxaline +Diaveridine HCl+ Vitamin K, Tramadol HCl +Dicyclomine HCl + Domperidone, Tramadol HCl +Paracetamol +Caffeine +Taurine for human use. By virtue of the circular, this action is based on recommendations from the Drugs Technical Advisory Board and the powers granted under section 26A of the Drugs and Cosmetics Act, 1940. The drug is deemed to have no therapeutic benefit and may pose risks to human health. Please refer to the attached document for more details.
Request a Demo
CDSL has reiterated the SEBI Circular on the norms for sharing and usage of price data for educational purposes, effective from July 01, 202
CDSL has issued a communique on the incorporation of Lock-In of Pre-Issue Capital during Initial Public Offering. Through this communique,
CDSL has reiterated the SEBI circular on the Fast-Track Mechanism for Processing of Placement Memorandum of AIFs filed with SEBI (“PaR
CDSL has reiterated the SEBI circular on the operationalisation of Past Risk and Return Verification Agency (“PaRRVAâ€). Key hig
7
I
2
Thank You for your interest in Complinity. Your CV has been forwarded to HR. In case your profile is shortlisted, HR shall contact you.
Thank You for your interest in Complinity. Your CV has been forwarded to HR.